Hot Features
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable an... Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.11 | 1.16 | 1.11 | 2616 | 1.12177662 | CS |
| 4 | -0.11 | -9.01639344262 | 1.22 | 1.22 | 1.05 | 2190 | 1.13343844 | CS |
| 12 | 0.16 | 16.8421052632 | 0.95 | 1.35 | 0.85 | 1514 | 1.06509153 | CS |
| 26 | -0.23 | -17.1641791045 | 1.34 | 1.35 | 0.85 | 1344 | 1.11255062 | CS |
| 52 | 0.05 | 4.71698113208 | 1.06 | 1.43 | 0.85 | 2077 | 1.16830195 | CS |
| 156 | 0 | 0 | 1.11 | 1.8 | 0.63 | 2668 | 1.22752661 | CS |
| 260 | -0.09 | -7.5 | 1.2 | 1.8 | 0.63 | 2751 | 1.18039031 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.